alpha-glucosidase

Overview

Alpha-glucosidase is an enzyme that plays a critical role in carbohydrate metabolism by catalyzing the hydrolysis of alpha-glucosidic linkages in oligosaccharides and disaccharides, leading to the release of glucose. This enzyme is primarily located in the brush border of the small intestine and is essential for the digestion of carbohydrates. Inhibitors of alpha-glucosidase, such as acarbose, are utilized in the management of type 2 diabetes mellitus (T2DM) to slow down carbohydrate absorption and help control postprandial blood glucose levels. By delaying glucose absorption, alpha-glucosidase inhibitors can improve glycemic control and reduce the risk of hyperglycemia in individuals with high-carbohydrate diets.

Focus of Latest Publications

Recent research demonstrates accelerating interest in developing alpha-glucosidase inhibitors across diverse therapeutic strategies. Natural products—extracted from chia seeds, Garcinia nujiangensis, hawthorn leaves, sea buckthorn juice, Boswellia serrata, and various medicinal and fruit tree species—have yielded potent inhibitors, with phenolic compounds including rosmarinic acid, gallic acid, caffeic acid, and chlorogenic acid identified as key contributors to enzyme inhibition. These plant-derived candidates frequently demonstrated inhibitory potency equivalent to or exceeding acarbose in biochemical assays, with some compounds showing IC₅₀ values in the low micromolar to submicromolar range. Notably, plant extracts often exhibit complementary antioxidant, anti-inflammatory, and antimicrobial activities alongside alpha-glucosidase inhibition, positioning them as multifunctional agents for addressing the broader metabolic dysregulation characteristic of type 2 diabetes.

Synthetic and semi-synthetic inhibitors represent a parallel research axis yielding compounds with substantially enhanced potency. Novel peptides, carbazole-thiazole hybrids, thiazole-hydrazine-isoindole scaffolds, methyl-glycosyl furanose sulfonium derivatives, and imidazothiazole-pyrrole compounds have demonstrated IC₅₀ or KI values 7–15 fold lower than acarbose. Mechanistic characterization revealed diverse inhibition modes—competitive, uncompetitive, and selective inhibition of specific alpha-glucosidase variants (maltase, sucrase, isomaltase)—with molecular docking and dynamics simulations revealing stable interactions at key catalytic residues. In vivo validation in animal models and zebrafish confirmed postprandial glucose reduction and antihyperglycemic efficacy comparable to established reference drugs.

Nanotechnology-based formulations emerged as a strategy to enhance therapeutic outcomes through improved bioavailability and controlled release. Ascorbic acid-functionalized zinc oxide nanoparticles, 1-deoxynojirimycin-loaded zwitterionic lipid nanoparticles, and selenium-conjugated polysaccharide nanoparticles demonstrated superior alpha-glucosidase inhibitory activity and oral bioavailability compared to free compound equivalents. These nano-enabled systems improved glycemic control and in some cases provided additional benefits including neuroprotection and amelioration of diabetic complications such as osteoporosis in preclinical models. Collectively, these studies reinforce alpha-glucosidase as a validated therapeutic target with expanding inhibitor development across natural products, synthetic scaffolds, and nanotechnology platforms.